The Drug and Medical Device Testing Services segmentation by type categorizes service offerings into distinct functional groups that aggregate to the market’s total revenue. In‑vitro diagnostic testing—covering assay development, analytical validation, and kit certification—addresses regulatory mandates for accuracy and contributes roughly 25 % of spend, driven by rapid growth in companion diagnostics. Bioanalytical services, which encompass LC‑MS/MS quantification, biomarker analysis, and pharmacokinetic modeling, represent about 20 % of the market, reflecting the need for precise drug concentration data across development phases. Toxicology testing, including acute, sub‑chronic and chronic studies, accounts for 15 % as safety assessment remains a prerequisite for IND filing. Medical device performance testing—mechanical, electrical, and biocompatibility evaluations—captures 18 % of revenue, aligning with the expanding portfolio of combination products. Software and cybersecurity validation for digital health devices occupies an emerging 7 % slice, underscoring regulatory focus on data integrity. Finally, clinical bioequivalence and pharmacodynamics studies comprise the remaining 15 %, ensuring generic and biosimilar approvals. Collectively, these type segments delineate the service portfolio and illustrate how specialization drives market diversification.